Table 1

Patient demographic and baseline characteristics

ParameterDCV+SOF
N=359
DCV+SOF+RBV
N=126
All patients
N=485
Age
 Median years (range)57.0 (27–87)57.5 (31–79)57.0 (27–87)
 ≥65 years, n (%)74 (21)21 (17)95 (20)
Male, n (%)235 (65)87 (69)322 (66)
Race, n (%)
 White338 (94)114 (90)452 (93)
 Black10 (3)3 (2)13 (3)
 Asian6 (2)5 (4)11 (2)
 Other5 (1)3 (2)8 (2)
 Not reported01 (1)1 (<1)
Body mass index, median kg/m2 (range)*25.7 (17–48)26.1 (16–44)25.9 (16–48)
HCV genotype, n (%)
 1284 (79)71 (56)355 (73)
  1a133 (37)28 (22)161 (33)
  1b137 (38)39 (31)176 (36)
  1 other/unknown subtype14 (4)4 (3)18 (4)
 202 (2)2 (<1)
 362 (17)40 (32)102 (21)
 412 (3)7 (6)19 (4)
 501 (1)1 (<1)
 Mixed1 (<1)2 (2)3 (1)
 Unknown03 (2)3 (1)
HCV RNA
 Median log10 IU/mL (range)5.8 (0–7.6)6.0 (0–7.2)5.9 (0–7.6)
 ≥2×106 IU/mL, n (%)91 (25)38 (30)129 (27)
 Not reported, n (%)7 (2)4 (3)11 (2)
Cirrhosis, n (%)†
 Present284 (79)105 (83)389 (80)
 Absent46 (13)14 (11)60 (12)
 Indeterminate16 (4)5 (4)21 (4)
 Not reported13 (4)2 (2)15 (3)
Child–Pugh class, n (%)‡
 A170 (60)53 (50)223 (57)
 B94 (33)49 (47)143 (37)
 C19 (7)3 (3)22 (6)
 Not reported1 (<1)01 (<1)
MELD score, n (%)‡
 <10129 (45)37 (35)166 (43)
 10–15133 (47)58 (55)191 (49)
 16–2017 (6)8 (8)25 (6)
 21–254 (1)04 (1)
 >251 (<1)1 (1)2 (<1)
 Not reported01 (1)1 (<1)
Albumin
 Median g/L (range)37.0 (18–56)35.0 (22–50)36.7 (18–56)
 ≥35 g/L, n (%)200 (56)57 (45)257 (53)
 <35 g/L, n (%)104 (29)54 (43)158 (33)
 Not reported55 (15)15 (12)70 (14)
Platelet count
 Median ×109/L (range)92.0 (16–455)88.5 (28–455)91.0 (16–455)
 ≥100, n (%)148 (41)56 (44) 204 (42)
 ≥50 to <100, n (%)151 (42)46 (37)197 (41)
 <50, n (%)47 (13)22 (17)69 (14)
 Not reported13 (4)2 (2)15 (3)
Creatinine clearance, mL/min/1.73 m2, n (%)
 ≥9090 (25)34 (27)124 (26)
 60–8970 (19)38 (30)108 (22)
 30–5944 (12)16 (13)60 (12)
 <305 (1)1 (1)6 (1)
 Not reported150 (42)37 (29)187 (39)
Hepatocellular carcinoma, n (%)20 (6)6 (5)26 (5)
Liver transplant recipient, n (%)62 (17)25 (20)87 (18)
 Fibrosing cholestatic hepatitis, n (%)4 (1)1 (1)5 (1)
Coinfection, n (%)§
 HIV/HCV39 (11)16 (13)55 (11)
 HBV/HCV9 (3)4 (3)13 (3)
Prior HCV therapy, n (%)
 Treatment-naïve108 (30)36 (29)144 (30)
 Treatment-experienced251 (70)90 (71)341 (70)
  Interferon/peginterferon±RBV164 (65)61 (68)225 (66)
  Protease inhibitor regimens55 (22)16 (18)71 (21)
  SOF regimens10 (4)1 (1)11 (3)
  Other regimens18 (7)9 (10)27 (8)
  Not reported4 (2)3 (3)7 (2)
  • *Body mass index not reported for 70 patients.

  • †Cirrhosis diagnosed by liver biopsy (Metavir >F3, Ishak >4 or the equivalent), n=51; FibroScan (>14.6 kPa), n=209 or FIB-4 score (>3.25), n=129.

  • ‡Percentages are based on patients with cirrhosis.

  • §HIV and HBV coinfection status not reported for 29 and 22 patients, respectively; three patients had HIV/HBV/HCV coinfection.

  • DCV, daclatasvir; MELD, Model for End-Stage Liver Disease; RBV, ribavirin; SOF, sofosbuvir.